The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation in the United States for Biotie’s BTT1023 drug candidate for the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic and progressive fibrotic liver disease for which there are currently no FDA-approved treatments.
BTT1023 is a fully human monoclonal antibody targeting Vascular Adhesion Protein-1 (VAP-1), and it is currently being studied for PSC in a Phase IIa study (the BUTEO study). The BUTEO study is conducted in partnership with the University of Birmingham, UK, and is supported by grant funding awarded by the UK’s National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation Programme, funded and managed by NIHR on behalf of the Medical Research Council-NIHR partnership.
The grant holder and co-investigator for the study is Professor David Adams, Director of the NIHR Biomedical Research Unit in Liver Disease and Centre for Liver Research at the University of Birmingham.
The two-stage study design for BUTEO includes a preplanned interim analysis and, based on current estimates, it is expected that the requisite number of patients will have been treated to enable the interim analysis in the first half of 2017.
In March 2015, the European Commission granted BTT1023 Orphan Drug Designation in the EU for the treatment of PSC. Biotie retains full rights to BTT1023.